Connect Biopharma is trading 8.86% higher at $1.08 before the September 30, 2026 open, with no company-specific announcement identified to explain the move. - Shares closed September 29 at $0.99 after an 8.15% decline. - The latest listed company release, on September 15, reported preliminary Phase 2 asthma-study data; it does not establish the reason for the gain. - Major U.S. indices are near flat, offering no clear broad-market explanation.